Phaseline

Companies › Hangzhou Qihan Biotech

Hangzhou Qihan Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QT-019B Cell Injection
Dual-target universal CAR-T cell therapy
–Phase 1Systemic Lupus Erythematosus (SLE)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07444307QT-019B Cell InjectionPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.